Publicaciones (22) Publicaciones de CARMEN AURORA RODRÍGUEZ CUETO

2024

  1. Involvement of CB1 and CB2 receptors in neuroprotective effects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice

    Biomedicine and Pharmacotherapy, Vol. 174

2023

  1. Endocannabinoid-Binding Receptors as Drug Targets

    Methods in molecular biology (Clifton, N.J.), Vol. 2576, pp. 67-94

  2. Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

    Journal of neuroinflammation, Vol. 20, Núm. 1, pp. 108

2022

  1. Editorial: Cannabinoids as potential treatment for neurological diseases

    Frontiers in Neuroscience

2021

  1. Bip heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis

    International Journal of Molecular Sciences, Vol. 22, Núm. 22

  2. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

  3. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis

    Brain Pathology, Vol. 31, Núm. 6

  4. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

  5. Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

    British Journal of Pharmacology

  6. Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1373-1387

2020

  1. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Endocannabinoid system in spinocerebellar ataxia type-3 and other autosomal-dominant cerebellar ataxias: Potential role in pathogenesis and expected relevance as neuroprotective targets

    Frontiers in Molecular Neuroscience, Vol. 12

  2. Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis

    British Journal of Pharmacology, Vol. 176, Núm. 10, pp. 1585-1600

2018

  1. Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis

    Biochemical Pharmacology, Vol. 157, pp. 217-226

2017

  1. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

    PLoS ONE, Vol. 12, Núm. 4

  2. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking

    European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412

  3. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis

    DMM Disease Models and Mechanisms, Vol. 10, Núm. 5, pp. 551-558

2016

  1. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

    Neuroscience, Vol. 339, pp. 191-209

  2. Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders

    Frontiers in Neuroscience, Vol. 10, Núm. SEP

2014

  1. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

    British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489